Elevai Labs, Inc. Common Stock

PMGC Holdings Inc. is a biopharmaceutical company focused on developing and acquiring aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. Its lead product is EL-22, a first-in-class engineered probiotic approach to address obesity's issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. The company also conducts medical scientific research and development, operates investment firms, provides packaging solutions to industrial and consumer markets, and designs and produces high-tolerance components for industrial and technological applications. It was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. Incorporated in 2020, it is based in Newport Beach, California.